Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Cancer Cell International
Published in: Cancer Cell International 1/2015

Open Access 01-12-2015 | Review

Resistance to cancer chemotherapy: failure in drug response from ADME to P-gp

Authors: Khalid O Alfarouk, Christian-Martin Stock, Sophie Taylor, Megan Walsh, Abdel Khalig Muddathir, Daniel Verduzco, Adil H H Bashir, Osama Y Mohammed, Gamal O Elhassan, Salvador Harguindey, Stephan J Reshkin, Muntaser E Ibrahim, Cyril Rauch

Published in: Cancer Cell International | Issue 1/2015

Login to get access

Abstract

Cancer chemotherapy resistance (MDR) is the innate and/or acquired ability of cancer cells to evade the effects of chemotherapeutics and is one of the most pressing major dilemmas in cancer therapy. Chemotherapy resistance can arise due to several host or tumor-related factors. However, most current research is focused on tumor-specific factors and specifically genes that handle expression of pumps that efflux accumulated drugs inside malignantly transformed types of cells. In this work, we suggest a wider and alternative perspective that sets the stage for a future platform in modifying drug resistance with respect to the treatment of cancer.
Literature
1.
Siegel R, Ma J, Zou Z, Jemal A (2014) Cancer statistics, 2014. CA Cancer J Clin 64:9–29PubMed
2.
Gatenby RA (2009) A change of strategy in the war on cancer. Nature 459:508–509PubMed
3.
Harguindey S, Orive G, Luis Pedraz J, Paradiso A, Reshkin SJ (2005) The role of pH dynamics and the Na+/H+ antiporter in the etiopathogenesis and treatment of cancer. Two faces of the same coin–one single nature. Biochim Biophys Acta 1756:1–24PubMed
4.
Undevia SD, Gomez-Abuin G, Ratain MJ (2005) Pharmacokinetic variability of anticancer agents. Nat Rev Cancer 5:447–458PubMed
5.
Paxton JW (1986) The effect of food on the bioavailability and kinetics of the anticancer drug amsacrine and a new analogue, N-5-dimethyl-9-[(2-methoxy-4-methylsulphonylamino)phenylamino]-4 acridinecarboxamide in rabbits. J Pharm Pharmacol 38:837–840PubMed
6.
McLeod HL, Evans WE (1999) Oral cancer chemotherapy: the promise and the pitfalls. Clin Cancer Res 5:2669–2671PubMed
7.
DeMario MD, Ratain MJ (1998) Oral chemotherapy: rationale and future directions. J Clin Oncol 16:2557–2567PubMed
8.
Fujiwara Y (1999) Current status of oral anticancer drugs in Japan. J Clin Oncol 17:3362–3365PubMed
9.
Sharma S (2001) Patient selection for oral chemotherapy. Oncology (Williston Park) 15(1 Suppl 2):33–35
10.
Thörn M, Finnström N, Lundgren S, Rane A, Lööf L (2005) Cytochromes P450 and MDR1 mRNA expression along the human gastrointestinal tract. Br J Clin Pharmacol 60:54–60PubMedCentralPubMed
11.
Wacher VJ, Salphati L, Benet LZ (2001) Active secretion and enterocytic drug metabolism barriers to drug absorption. Adv Drug Deliv Rev 46:89–102PubMed
12.
Sparreboom A, van Asperen J, Mayer U, Schinkel AH, Smit JW, Meijer DKF et al (1997) Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine. Proc Natl Acad Sci USA 94:2031–2035PubMedCentralPubMed
13.
Burger H, Nooter K (2004) Pharmacokinetic resistance to imatinib mesylate: role of the ABC drug pumps ABCG2 (BCRP) and ABCB1 (MDR1) in the oral bioavailability of imatinib. Cell Cycle 3:1502–1505PubMed
14.
Dietrich CG, Geier A, Oude Elferink RPJ (2003) ABC of oral bioavailability: transporters as gatekeepers in the gut. Gut 52:1788–1795PubMedCentralPubMed
15.
Cascorbi I, Gerloff T, Johne A, Meisel C, Hoffmeyer S, Schwab M et al (2001) Frequency of single nucleotide polymorphisms in the P-glycoprotein drug transporter MDR1 gene in white subjects. Clin Pharmacol Ther 69:169–174PubMed
16.
Ling J, Fettner S, Lum BL, Riek M, Rakhit A (2008) Effect of food on the pharmacokinetics of erlotinib, an orally active epidermal growth factor receptor tyrosine-kinase inhibitor, in healthy individuals. Anticancer Drugs 19:209–216PubMed
17.
Jain RK, Brar SS, Lesko LJ (2010) Food and oral antineoplastics: more than meets the eye. Clin Cancer Res 16:4305–4307PubMed
18.
Kang SP, Ratain MJ (2010) Inconsistent labeling of food effect for oral agents across therapeutic areas: differences between oncology and non-oncology products. Clin Cancer Res 16:4446–4451PubMedCentralPubMed
19.
Herben VM, Rosing H, ten Bokkel Huinink WW, van Zomeren DM, Batchelor D, Doyle E (1999) Oral topotecan: bioavailablity and effect of food co-administration. Br J Cancer 80:1380–1386PubMedCentralPubMed
20.
Kivistö KT, Niemi M, Fromm MF (2004) Functional interaction of intestinal CYP3A4 and P-glycoprotein. Fundam Clin Pharmacol 18:621–626PubMed
21.
He K, Iyer KR, Hayes RN, Sinz MW, Woolf TF, Hollenberg PF (1998) Inactivation of cytochrome P450 3A4 by bergamottin, a component of grapefruit juice. Chem Res Toxicol 11:252–259PubMed
22.
Fujita K (2004) Food-drug interactions via human cytochrome P450 3A (CYP3A). Drug Metabol Drug Interact 20:195–217PubMed
23.
Singh BN, Malhotra BK (2004) Effects of food on the clinical pharmacokinetics of anticancer agents: underlying mechanisms and implications for oral chemotherapy. Clin Pharmacokinet 43:1127–1156PubMed
24.
Ruggiero A, Cefalo MG, Coccia P, Mastrangelo S, Maurizi P, Riccardi R (2012) The role of diet on the clinical pharmacology of oral antineoplastic agents. Eur J Clin Pharmacol 68:115–122PubMed
25.
Wilson K (1984) Sex-related differences in drug disposition in man. Clin Pharmacokinet 9:189–202PubMed
26.
Pleym H, Spigset O, Kharasch ED, Dale O (2003) Gender differences in drug effects: implications for anesthesiologists. Acta Anaesthesiol Scand 47:241–259PubMed
27.
Alfarouk KO, Shayoub MEAA, Muddathir AK, Elhassan GO, Bashir AHHH (2011) Evolution of tumor metabolism might reflect carcinogenesis as a reverse evolution process (dismantling of multicellularity). Cancers (Basel) 3:3002–3017
28.
29.
Beierle I, Meibohm B, Derendorf H (1999) Gender differences in pharmacokinetics and pharmacodynamics. Int J Clin Pharmacol Ther 37:529–547PubMed
30.
Hanley MJ, Abernethy DR, Greenblatt DJ (2010) Effect of obesity on the pharmacokinetics of drugs in humans. Clin Pharmacokinet 49:71–87PubMed
31.
Theologides A (1977) Nutritional management of the patient with advanced cancer. Postgrad Med 61:97–101PubMed
32.
Fearon KC (1992) The Sir David Cuthbertson Medal Lecture 1991. The mechanisms and treatment of weight loss in cancer. Proc Nutr Soc 51:251–265PubMed
33.
Fearon KC, Voss AC, Hustead DS (2006) Definition of cancer cachexia: effect of weight loss, reduced food intake, and systemic inflammation on functional status and prognosis. Am J Clin Nutr 83:1345–1350PubMed
34.
Powis G, Reece P, Ahmann DL, Ingle JN (1987) Effect of body weight on the pharmacokinetics of cyclophosphamide in breast cancer patients. Cancer Chemother Pharmacol 20:219–222PubMed
35.
Felici A, Verweij J, Sparreboom A (2002) Dosing strategies for anticancer drugs: the good, the bad and body-surface area. Eur J Cancer 38:1677–1684PubMed
36.
Tillement JP, Zini R, d’ Athis P, Vassent G (1974) Binding of certain acidic drugs to human albumin: theoretical and practical estimation of fundamental parameters. Eur J Clin Pharmacol 7:307–313PubMed
37.
Ruiz-Cabello F, Erill S (1984) Abnormal serum protein binding of acidic drugs in diabetes mellitus. Clin Pharmacol Ther 36:691–695PubMed
38.
39.
Goldwasser P, Feldman J (1997) Association of serum albumin and mortality risk. J Clin Epidemiol 50:693–703PubMed
40.
Lis CG, Grutsch JF, Vashi PG, Lammersfeld CA (2003) Is serum albumin an independent predictor of survival in patients with breast cancer? JPEN J Parenter Enteral Nutr 27:10–15PubMed
41.
Grimm G, Haslacher H, Kampitsch T, Endler G, Marsik C, Schickbauer T et al (2009) Sex differences in the association between albumin and all-cause and vascular mortality. Eur J Clin Invest 39:860–865PubMed
42.
Liu B, Earl HM, Poole CJ, Dunn J, Kerr DJ (1995) Etoposide protein binding in cancer patients. Cancer Chemother Pharmacol 36:506–512PubMed
43.
Liliemark E, Söderhäll S, Sirzea F, Gruber A, Osby E, Björkholm M et al (1996) Higher in vivo protein binding of etoposide in children compared with adult cancer patients. Cancer Lett 106:97–100PubMed
44.
Gambacorti-Passerini C, Zucchetti M, Russo D, Frapolli R, Verga M, Bungaro S et al (2003) Alpha1 acid glycoprotein binds to imatinib (STI571) and substantially alters its pharmacokinetics in chronic myeloid leukemia patients. Clin Cancer Res 9:625–632PubMed
45.
Li J, Brahmer J, Messersmith W, Hidalgo M, Baker SD (2006) Binding of gefitinib, an inhibitor of epidermal growth factor receptor-tyrosine kinase, to plasma proteins and blood cells: in vitro and in cancer patients. Invest New Drugs 24:291–297PubMed
46.
Wu J, Lorusso PM, Matherly LH, Li J (2012) Implications of plasma protein binding for pharmacokinetics and pharmacodynamics of the γ-secretase inhibitor RO4929097. Clin Cancer Res 18:2066–2079PubMed
47.
Levi F, Schibler U (2007) Circadian rhythms: mechanisms and therapeutic implications. Annu Rev Pharmacol Toxicol 47:593–628PubMed
48.
Sukumaran S, Almon RR, DuBois DC, Jusko WJ (2010) Circadian rhythms in gene expression: relationship to physiology, disease, drug disposition and drug action. Adv Drug Deliv Rev 62:904–917PubMedCentralPubMed
49.
Takahashi JS, Hong H-K, Ko CH, McDearmon EL (2008) The genetics of mammalian circadian order and disorder: implications for physiology and disease. Nat Rev Genet 9:764–775PubMedCentralPubMed
50.
51.
Straub RH, Cutolo M (2007) Circadian rhythms in rheumatoid arthritis: implications for pathophysiology and therapeutic management. Arthritis Rheum 56:399–408PubMed
52.
Lévi F, Okyar A, Dulong S, Innominato PF, Clairambault J (2010) Circadian timing in cancer treatments. Annu Rev Pharmacol Toxicol 50:377–421PubMed
53.
Prémaud A, Rousseau A, Gicquel M, Ragot S, Manceau J, Laurentie M et al (2002) An animal model for the study of chronopharmacokinetics of drugs and application to methotrexate and vinorelbine. Toxicol Appl Pharmacol 183:189–197PubMed
54.
Baraldo M (2008) The influence of circadian rhythms on the kinetics of drugs in humans. Expert Opin Drug Metab Toxicol 4:175–192PubMed
55.
Erkekoglu P, Baydar T (2012) Chronopharmacokinetics of drugs in toxicological aspects: a short review for pharmacy practitioners. J Res Pharm Pract 1:3–9PubMedCentralPubMed
56.
Touitou Y, Touitou C, Bogdan A, Reinberg A, Auzeby A, Beck H et al (1986) Differences between young and elderly subjects in seasonal and circadian variations of total plasma proteins and blood volume as reflected by hemoglobin, hematocrit, and erythrocyte counts. Clin Chem 32:801–804PubMed
57.
Bruguerolle B, Arnaud C, Levi F, Focan C, Touitou Y, Bouvenot G (1989) Physiopathological alterations of alpha 1 acid glycoprotein temporal variations: implications for chronopharmacology. Prog Clin Biol Res 300:199–214PubMed
58.
Hecquet B, Meynadier J, Bonneterre J, Adenis L, Demaille A (1985) Time dependency in plasmatic protein binding of cisplatin. Cancer Treat Rep 69:79–83PubMed
59.
Hecquet B, Sucche M (1986) Theoretical study of the influence of the circadian rhythm of plasma protein binding on cisplatin area under the curve. J Pharmacokinet Biopharm 14:79–93PubMed
60.
Lévi F (2006) Chronotherapeutics: the relevance of timing in cancer therapy. Cancer Causes Control 17:611–621PubMed
61.
Guengerich FP (2007) Mechanisms of cytochrome P450 substrate oxidation: MiniReview. J Biochem Mol Toxicol 21:163–168PubMed
62.
Guengerich FP (2008) Cytochrome p450 and chemical toxicology. Chem Res Toxicol 21:70–83PubMed
63.
Jancova P, Anzenbacher P, Anzenbacherova E (2010) Phase II drug metabolizing enzymes. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 154:103–116PubMed
64.
Gonzalez FJ (2006) Goodman and Gilman’s Pharmacological Basis of Therapeutics. In: Brunton LLLL, Lazo JS (eds) The McGraw-Hill Companies, Inc‎, New York, pp ‎71–92‎
65.
Rooseboom M, Commandeur JNM, Vermeulen NPE (2004) Enzyme-catalyzed activation of anticancer prodrugs. Pharmacol Rev 56:53–102PubMed
66.
Akhdar H, Legendre C, Caroline Aninat FM (2012) Topics on drug metabolism‎. In: Paxton J (ed) INTECH, pp ‎137–170‎
67.
McFadyen MCE, Melvin WT, Murray GI (2004) Cytochrome P450 enzymes: novel options for cancer therapeutics. Mol Cancer Ther 3:363–371PubMed
68.
Rodriguez-Antona C, Ingelman-Sundberg M (2006) Cytochrome P450 pharmacogenetics and cancer. Oncogene 25:1679–1691PubMed
69.
Lin JH, Lu AY (2001) Interindividual variability in inhibition and induction of cytochrome P450 enzymes. Annu Rev Pharmacol Toxicol 41:535–567PubMed
70.
Ingelman-Sundberg M, Sim SC, Gomez A, Rodriguez-Antona C (2007) Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects. Pharmacol Ther 116:496–526PubMed
71.
Plant N (2007) The human cytochrome P450 sub-family: transcriptional regulation, inter-individual variation and interaction networks. Biochim Biophys Acta 1770:478–488PubMed
72.
Hayes JD, Pulford DJ (1995) The glutathione S-transferase supergene family: regulation of GST and the contribution of the isoenzymes to cancer chemoprotection and drug resistance. Crit Rev Biochem Mol Biol 30:445–600PubMed
73.
Xu C, Li CY-T, Kong A-NT (2005) Induction of phase I, II and III drug metabolism/transport by xenobiotics. Arch Pharm Res 28:249–268PubMed
74.
Nakagawa K, Saijo N, Tsuchida S, Sakai M, Tsunokawa Y, Yokota J et al (1990) Glutathione-S-transferase pi as a determinant of drug resistance in transfectant cell lines. J Biol Chem 265:4296–4301PubMed
75.
Uozaki H, Horiuchi H, Ishida T, Iijima T, Imamura T, Machinami R (1997) Overexpression of resistance-related proteins (metallothioneins, glutathione-S-transferase pi, heat shock protein 27, and lung resistance-related protein) in osteosarcoma. Relationship with poor prognosis. Cancer 79:2336–2344PubMed
76.
Harkey MA, Czerwinski M, Slattery J, Kiem H-P (2005) Overexpression of glutathione-S-transferase, MGSTII, confers resistance to busulfan and melphalan. Cancer Invest 23:19–25PubMed
77.
Kauvar LM, Morgan AS, Sanderson PE, Henner WD (1998) Glutathione based approaches to improving cancer treatment. Chem Biol Interact 111–112:225–238PubMed
78.
Riddick DS, Lee C, Ramji S, Chinje EC, Cowen RL, Williams KJ et al (2005) Cancer chemotherapy and drug metabolism. Drug Metab Dispos 33:1083–1096PubMed
79.
Kodym R, Calkins P, Story M (1999) The cloning and characterization of a new stress response protein. A mammalian member of a family of theta class glutathione s-transferase-like proteins. J Biol Chem 274:5131–5137PubMed
80.
Cumming RC, Lightfoot J, Beard K, Youssoufian H, O’Brien PJ, Buchwald M (2001) Fanconi anemia group C protein prevents apoptosis in hematopoietic cells through redox regulation of GSTP1. Nat Med 7:814–820PubMed
81.
Townsend DM, Tew KD (2003) The role of glutathione-S-transferase in anti-cancer drug resistance. Oncogene 22:7369–7375PubMed
82.
Gunnarsdottir S, Elfarra AA (1999) Glutathione-dependent metabolism of cis-3-(9H-purin-6-ylthio)acrylic acid to yield the chemotherapeutic drug 6-mercaptopurine: evidence for two distinct mechanisms in rats. J Pharmacol Exp Ther 290:950–957PubMed
83.
Tew KD (2005) TLK-286: a novel glutathione S-transferase-activated prodrug. Expert Opin Investig Drugs 14:1047–1054PubMed
84.
Nelson HH, Wiencke JK, Christiani DC, Cheng TJ, Zuo ZF, Schwartz BS et al (1995) Ethnic differences in the prevalence of the homozygous deleted genotype of glutathione S-transferase theta. Carcinogenesis 16:1243–1245PubMed
85.
Kempkes M, Golka K, Reich S, Reckwitz T, Bolt HM (1996) Glutathione S-transferase GSTM1 and GSTT1 null genotypes as potential risk factors for urothelial cancer of the bladder. Arch Toxicol 71:123–126PubMed
86.
LA Magno V, Talbot J, Talbot T, Borges Santos AM, Souza RP, Marin LJ (2009) Glutathione s-transferase variants in a brazilian population. Pharmacology 83:231–236PubMed
87.
Ying X-J, Dong P, Shen B, Xu C-Z, Xu H-M, Zhao S-W (2012) Glutathione S-transferase M1 gene polymorphism and laryngeal cancer risk: a meta-analysis. PLoS One 7:e42826PubMedCentralPubMed
88.
Liu J, Chen H, Miller DS, Saavedra JE, Keefer LK, Johnson DR et al (2001) Overexpression of glutathione S-transferase II and multidrug resistance transport proteins is associated with acquired tolerance to inorganic arsenic. Mol Pharmacol 60:302–309PubMed
89.
Lévi F, Altinok A, Clairambault J, Goldbeter A (2008) Implications of circadian clocks for the rhythmic delivery of cancer therapeutics. Philos Trans A Math Phys Eng Sci 366:3575–3598PubMed
90.
Zeng Z-L, Sun J, Guo L, Li S, Wu M, Qiu F et al (2005) Circadian rhythm in dihydropyrimidine dehydrogenase activity and reduced glutathione content in peripheral blood of nasopharyngeal carcinoma patients. Chronobiol Int 22:741–754PubMed
91.
Smaaland R, Sothern RB, Laerum OD, Abrahamsen JF (2002) Rhythms in human bone marrow and blood cells. Chronobiol Int 19:101–127PubMed
92.
Krishna DR, Klotz U (1994) Extrahepatic metabolism of drugs in humans. Clin Pharmacokinet 26:144–160PubMed
93.
Pacifici GM, Franchi M, Bencini C, Repetti F, Di Lascio N, Muraro GB (1988) Tissue distribution of drug-metabolizing enzymes in humans. Xenobiotica 18:849–856PubMed
94.
Fisher MB, Paine MF, Strelevitz TJ, Wrighton SA (2001) The role of hepatic and extrahepatic UDP-glucuronosyltransferases in human drug metabolism. Drug Metab Rev 33:273–297PubMed
95.
Ritter JK (2007) Intestinal UGTs as potential modifiers of pharmacokinetics and biological responses to drugs and xenobiotics. Expert Opin Drug Metab Toxicol 3:93–107PubMed
96.
Dai D, Zeldin DC, Blaisdell JA, Chanas B, Coulter SJ, Ghanayem BI et al (2001) Polymorphisms in human CYP2C8 decrease metabolism of the anticancer drug paclitaxel and arachidonic acid. Pharmacogenetics 11:597–607PubMed
97.
Gréen H, Söderkvist P, Rosenberg P, Mirghani RA, Rymark P, Lundqvist EA et al (2009) Pharmacogenetic studies of Paclitaxel in the treatment of ovarian cancer. Basic Clin Pharmacol Toxicol 104:130–137PubMed
98.
Kusuhara H, Sugiyama Y (2002) Role of transporters in the tissue-selective distribution and elimination of drugs: transporters in the liver, small intestine, brain and kidney. J Control Release 78:43–54PubMed
99.
Vaisman BL, Lambert G, Amar M, Joyce C, Ito T, Shamburek RD et al (2001) ABCA1 overexpression leads to hyperalphalipoproteinemia and increased biliary cholesterol excretion in transgenic mice. J Clin Invest 108:303–309PubMedCentralPubMed
100.
Yu L, Li-Hawkins J, Hammer RE, Berge KE, Horton JD, Cohen JC et al (2002) Overexpression of ABCG5 and ABCG8 promotes biliary cholesterol secretion and reduces fractional absorption of dietary cholesterol. J Clin Invest 110:671–680PubMedCentralPubMed
101.
Vlaming MLH, Mohrmann K, Wagenaar E, de Waart DR, Elferink RPJO, Lagas JS et al (2006) Carcinogen and anticancer drug transport by Mrp2 in vivo: studies using Mrp2 (Abcc2) knockout mice. J Pharmacol Exp Ther 318:319–327PubMed
102.
Figge A, Lammert F, Paigen B, Henkel A, Matern S, Korstanje R et al (2004) Hepatic overexpression of murine Abcb11 increases hepatobiliary lipid secretion and reduces hepatic steatosis. J Biol Chem 279:2790–2799PubMed
103.
Vree TB, Van Ewijk-Beneken Kolmer EW, Wuis EW, Hekster YA, Broekman MM (1993) Interindividual variation in the capacity-limited renal glucuronidation of probenecid by humans. Pharm World Sci 15:197–202PubMed
104.
Morris ME, Lee H-J, Predko LM (2003) Gender differences in the membrane transport of endogenous and exogenous compounds. Pharmacol Rev 55:229–240PubMed
105.
Johnson JA (2000) Predictability of the effects of race or ethnicity on pharmacokinetics of drugs. Int J Clin Pharmacol Ther 38:53–60PubMed
106.
Loadman PM, Bibby MC (1994) Pharmacokinetic drug interactions with anticancer drugs. Clin Pharmacokinet 26:486–500PubMed
107.
Siemann DW (2006) Tumor vasculature : a target for anticancer therapies. In: Vascular-targeted therapies in oncology. John Wiley & Sons, Ltd, Chichester, pp 1–8
108.
109.
Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144:646–674PubMed
110.
Ma J, Waxman DJ (2008) Combination of antiangiogenesis with chemotherapy for more effective cancer treatment. Mol Cancer Ther 7:3670–3684PubMedCentralPubMed
111.
Kerbel RS (2006) Antiangiogenic therapy: a universal chemosensitization strategy for cancer? Science 312:1171–1175PubMed
112.
Lloyd MC, Alfarouk KO, Verduzco D, Bui MM, Gillies RJ, Ibrahim ME et al (2014) Vascular measurements correlate with estrogen receptor status. BMC Cancer 14:279PubMedCentralPubMed
113.
Robey IF, Baggett BK, Kirkpatrick ND, Roe DJ, Dosescu J, Sloane BF et al (2009) Bicarbonate increases tumor pH and inhibits spontaneous metastases. Cancer Res 69:2260–2268PubMedCentralPubMed
114.
Lippens RJ (1984) Methotrexate. I. Pharmacology and pharmacokinetics. Am J Pediatr Hematol Oncol 6:379–395PubMed
115.
Singh MS, Francis PA, Michael M (2011) Tamoxifen, cytochrome P450 genes and breast cancer clinical outcomes. Breast 20:111–118PubMed
116.
Stearns V, Johnson MD, Rae JM, Morocho A, Novielli A, Bhargava P et al (2003) Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. J Natl Cancer Inst 95:1758–1764PubMed
117.
Caraci F, Crupi R, Drago F, Spina E (2011) Metabolic drug interactions between antidepressants and anticancer drugs: focus on selective serotonin reuptake inhibitors and hypericum extract. Curr Drug Metab 12:570–577PubMed
118.
Yap KYL, Tay WL, Chui WK, Chan A (2011) Clinically relevant drug interactions between anticancer drugs and psychotropic agents. Eur J Cancer Care (Engl) 20:6–32
119.
Yamazaki M, Suzuki H, Sugiyama Y (1996) Recent advances in carrier-mediated hepatic uptake and biliary excretion of xenobiotics. Pharm Res 13:497–513PubMed
120.
König J, Nies AT, Cui Y, Leier I, Keppler D (1999) Conjugate export pumps of the multidrug resistance protein (MRP) family: localization, substrate specificity, and MRP2-mediated drug resistance. Biochim Biophys Acta 1461:377–394PubMed
121.
Hirano M, Maeda K, Hayashi H, Kusuhara H, Sugiyama Y (2005) Bile salt export pump (BSEP/ABCB11) can transport a nonbile acid substrate, pravastatin. J Pharmacol Exp Ther 314:876–882PubMed
122.
Kamisako T, Ogawa H (2004) Effects of pravastatin and bezafibrate on biliary lipid excretion and hepatic expression of Abcg5 and Abcg8 in the rat. J Gastroenterol Hepatol 19:879–883PubMed
123.
Raghunand N, Martínez-Zaguilán R, Wright SH, Gillies RJ (1999) pH and drug resistance. II. Turnover of acidic vesicles and resistance to weakly basic chemotherapeutic drugs. Biochem Pharmacol 57:1047–1058PubMed
124.
Mahoney BP, Raghunand N, Baggett B, Gillies RJ (2003) Tumor acidity, ion trapping and chemotherapeutics. I. Acid pH affects the distribution of chemotherapeutic agents in vitro. Biochem Pharmacol 66:1207–1218PubMed
125.
Gottesman MM (2002) Mechanisms of cancer drug resistance. Annu Rev Med 53:615–627PubMed
126.
Stewart DJ (2007) Saturable passive resistance in chemotherapy of epithelial maligancies. In: Parsons RA (ed) Progress in cancer drug resistance research. Nova Science, New York, pp ‎29–41‎
127.
De Visser KE, Jonkers J (2009) Towards understanding the role of cancer-associated inflammation in chemoresistance. Curr Pharm Des 15:1844–1853PubMed
128.
Barlow M, Hall BG (2002) Phylogenetic analysis shows that the OXA β-lactamase genes have been on plasmids for millions of years. J Mol Evol 55:314–321PubMed
129.
Hall BG, Barlow M (2004) Evolution of the serine beta-lactamases: past, present and future. Drug Resist Updat 7:111–123PubMed
130.
Baltz RH (2008) Renaissance in antibacterial discovery from actinomycetes. Curr Opin Pharmacol 557–563
131.
D’Costa VM, King CE, Kalan L, Morar M, Sung WWL, Schwarz C et al (2011) Antibiotic resistance is ancient. Nature 477:457–461PubMed
132.
Bhullar K, Waglechner N, Pawlowski A, Koteva K, Banks ED, Johnston MD et al (2012) Antibiotic resistance is prevalent in an isolated cave microbiome. PLoS One 7:e34953PubMedCentralPubMed
133.
Ueda K, Clark DP, Chen CJ, Roninson IB, Gottesman MM, Pastan I (1987) The human multidrug resistance (mdr1) gene. cDNA cloning and transcription initiation. J Biol Chem 262:505–508PubMed
134.
Goldstein LJ, Galski H, Fojo A, Willingham M, Lai SL, Gazdar A et al (1989) Expression of a multidrug resistance gene in human cancers. J Natl Cancer Inst 81:116–124PubMed
135.
Zhou S-F (2008) Structure, function and regulation of P-glycoprotein and its clinical relevance in drug disposition. Xenobiotica 38:802–832PubMed
136.
Thiebaut F, Tsuruo T, Hamada H, Gottesman MM, Pastan I, Willingham MC (1987) Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc Natl Acad Sci USA 84:7735–7738PubMedCentralPubMed
137.
Schinkel A (1999) P-Glycoprotein, a gatekeeper in the blood-brain barrier. Adv Drug Deliv Rev 36:179–194PubMed
138.
Maliepaard M, Scheffer GL, Faneyte IF, van Gastelen MA, Pijnenborg AC, Schinkel AH et al (2001) Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues. Cancer Res 61:3458–3464PubMed
139.
Schuetz EG, Schinkel AH, Relling MV, Schuetz JD (1996) P-glycoprotein: a major determinant of rifampicin-inducible expression of cytochrome P4503A in mice and humans. Proc Natl Acad Sci USA 93:4001–4005PubMedCentralPubMed
140.
Munteanu E, Verdier M, Grandjean-Forestier F, Stenger C, Jayat-Vignoles C, Huet S et al (2006) Mitochondrial localization and activity of P-glycoprotein in doxorubicin-resistant K562 cells. Biochem Pharmacol 71:1162–1174PubMed
141.
Bendayan R, Ronaldson PT, Gingras D, Bendayan M (2006) In situ localization of P-glycoprotein (ABCB1) in human and rat brain. J Histochem Cytochem 54:1159–1167PubMedCentralPubMed
142.
Solazzo M, Fantappiè O, D’Amico M, Sassoli C, Tani A, Cipriani G et al (2009) Mitochondrial expression and functional activity of breast cancer resistance protein in different multiple drug-resistant cell lines. Cancer Res 69:7235–7242PubMed
143.
Shen Y, Chu Y, Yang Y, Wang Z (2012) Mitochondrial localization of P-glycoprotein in the human breast cancer cell line MCF-7/ADM and its functional characterization. Oncol Rep 27:1535–1540PubMed
144.
Solazzo M, Fantappiè O, Lasagna N, Sassoli C, Nosi D, Mazzanti R (2006) P-gp localization in mitochondria and its functional characterization in multiple drug-resistant cell lines. Exp Cell Res 312:4070–4078PubMed
145.
Babakhanian K, Bendayan M, Bendayan R (2007) Localization of P-glycoprotein at the nuclear envelope of rat brain cells. Biochem Biophys Res Commun 361:301–306PubMed
146.
Wei LY, Roepe PD (1994) Low external pH and osmotic shock increase the expression of human MDR protein. Biochemistry 33:7229–7238PubMed
147.
Cole SP, Bhardwaj G, Gerlach JH, Mackie JE, Grant CE, Almquist KC et al (1992) Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science 258:1650–1654PubMed
148.
Young LC, Campling BG, Cole SP, Deeley RG, Gerlach JH (2001) Multidrug resistance proteins MRP3, MRP1, and MRP2 in lung cancer: correlation of protein levels with drug response and messenger RNA levels. Clin Cancer Res 7:1798–1804PubMed
149.
Copsel S, Garcia C, Diez F, Vermeulem M, Baldi A, Bianciotti LG et al (2011) Multidrug resistance protein 4 (MRP4/ABCC4) regulates cAMP cellular levels and controls human leukemia cell proliferation and differentiation. J Biol Chem 286:6979–6988PubMedCentralPubMed
150.
Sauna ZE, Ambudkar SV (2007) About a switch: how P-glycoprotein (ABCB1) harnesses the energy of ATP binding and hydrolysis to do mechanical work. Mol Cancer Ther 6:13–23PubMed
151.
Keppler D, Leier I, Jedlitschky G, König J (1998) ATP-dependent transport of glutathione S-conjugates by the multidrug resistance protein MRP1 and its apical isoform MRP2. Chem Biol Interact 111–112:153–161PubMed
152.
Keppler D (1999) Export pumps for glutathione S-conjugates. Free Radic Biol Med 27:985–991PubMed
153.
Coley HM (2008) Mechanisms and strategies to overcome chemotherapy resistance in metastatic breast cancer. Cancer Treat Rev 34:378–390PubMed
154.
Cole SPC, Deeley RG (2006) Transport of glutathione and glutathione conjugates by MRP1. Trends Pharmacol Sci 27:438–446PubMed
155.
Litman T, Druley TE, Stein WD, Bates SE (2001) From MDR to MXR: new understanding of multidrug resistance systems, their properties and clinical significance. Cell Mol Life Sci 58:931–959PubMed
156.
Sauna ZE, Smith MM, Müller M, Kerr KM, Ambudkar SV (2001) The mechanism of action of multidrug-resistance-linked P-glycoprotein. J Bioenerg Biomembr 33:481–491PubMed
157.
Glavinas H, Krajcsi P, Cserepes J, Sarkadi B (2004) The role of ABC transporters in drug resistance, metabolism and toxicity. Curr Drug Deliv 1:27–42PubMed
158.
Maini R, St Clair EW, Breedveld F, Furst D, Kalden J, Weisman M (1999) Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet 354:1932–1939PubMed
159.
Cress RH, Deaver NL (1964) Methotrexate in the management of severe psoriasis and arthritis: report of a case. South Med J 57:1088–1090PubMed
160.
Dale J, Alcorn N, Capell H, Madhok R (2007) Combination therapy for rheumatoid arthritis: methotrexate and sulfasalazine together or with other DMARDs. Nat Clin Pract Rheumatol 3:450–458 quiz, following 478 PubMed
161.
Curt GA, Carney DN, Cowan KH, Jolivet J, Bailey BD, Drake JC et al (1983) Unstable methotrexate resistance in human small-cell carcinoma associated with double minute chromosomes. N Engl J Med 308:199–202PubMed
162.
Schimke RT (1984) Gene amplification, drug resistance, and cancer. Cancer Res 44:1735–1742PubMed
163.
Kobayashi S, Boggon TJ, Dayaram T, Jänne PA, Kocher O, Meyerson M et al (2005) EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 352:786–792PubMed
164.
Longley DB, Harkin DP, Johnston PG (2003) 5-fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer 3:330–338PubMed
165.
Watson RG, Muhale F, Thorne LB, Yu J, O’Neil BH, Hoskins JM et al (2010) Amplification of thymidylate synthetase in metastatic colorectal cancer patients pretreated with 5-fluorouracil-based chemotherapy. Eur J Cancer 46:3358–3364PubMedCentralPubMed
166.
Wang T-L, Diaz LA, Romans K, Bardelli A, Saha S, Galizia G et al (2004) Digital karyotyping identifies thymidylate synthase amplification as a mechanism of resistance to 5-fluorouracil in metastatic colorectal cancer patients. Proc Natl Acad Sci USA 101:3089–3094PubMedCentralPubMed
167.
Reshkin SJ, Cardone RA, Harguindey S (2013) Na+-H+ exchanger, pH regulation and cancer. Recent Pat Anticancer Drug Discov 8:85–99PubMed
168.
Neri D, Supuran CT (2011) Interfering with pH regulation in tumours as a therapeutic strategy. Nat Rev Drug Discov 10:767–777PubMed
169.
Huber V, De Milito A, Harguindey S, Reshkin SJ, Wahl ML, Rauch C et al (2010) Proton dynamics in cancer. J Transl Med 8:57PubMedCentralPubMed
170.
Alfarouk KO, Muddathir AK, Shayoub MEA (2011) Tumor acidity as evolutionary spite. Cancers (Basel) 3:408–414
171.
Hao N-B, Lü M-H, Fan Y-H, Cao Y-L, Zhang Z-R, Yang S-M (2012) Macrophages in tumor microenvironments and the progression of tumors. Clin Dev Immunol 2012:948098PubMedCentralPubMed
172.
Correia AL, Bissell MJ (2012) The tumor microenvironment is a dominant force in multidrug resistance. Drug Resist Updat 15:39–49PubMedCentralPubMed
173.
Gillies RJ, Raghunand N, Karczmar GS, Bhujwalla ZM (2002) MRI of the tumor microenvironment. J Magn Reson Imaging 16:430–450PubMed
174.
Raghunand N, Gillies RJ (2000) pH and drug resistance in tumors. Drug Resist Updat 3:39–47PubMed
175.
Wojtkowiak JW, Verduzco D, Schramm KJ, Gillies RJ (2011) Drug resistance and cellular adaptation to tumor acidic pH microenvironment. Mol Pharm 8:2032–2038PubMedCentralPubMed
176.
Raghunand N, Mahoney BP, Gillies RJ (2003) Tumor acidity, ion trapping and chemotherapeutics. II. pH-dependent partition coefficients predict importance of ion trapping on pharmacokinetics of weakly basic chemotherapeutic agents. Biochem Pharmacol 66:1219–1229PubMed
177.
Gong Y, Duvvuri M, Krise JP (2003) Separate roles for the Golgi apparatus and lysosomes in the sequestration of drugs in the multidrug-resistant human leukemic cell line HL-60. J Biol Chem 278:50234–50239PubMed
178.
Parkins CS, Chadwick JA, Chaplin DJ (1996) Inhibition of intracellular pH control and relationship to cytotoxicity of chlorambucil and vinblastine. Br J Cancer Suppl 27:S75–S77PubMedCentralPubMed
179.
Alfarouk KO, Verduzco D, Rauch C, Muddathir AK, Adil HHB et al (2014) Glycolysis, tumor metabolism, cancer growth and dissemination. A new pH-based etiopathogenic perspective and therapeutic approach to an old cancer question. Oncoscience 1:777–802PubMedCentralPubMed
180.
Harguindey S, Pedraz JL, García Cañero R, Pérez de Diego J, Cragoe EJ (1995) Hydrogen ion-dependent oncogenesis and parallel new avenues to cancer prevention and treatment using a H(+)-mediated unifying approach: pH-related and pH-unrelated mechanisms. Crit Rev Oncog 6:1–33PubMed
181.
Harguindey S, Arranz JL, Polo Orozco JD, Rauch C, Fais S, Cardone RA et al (2013) Cariporide and other new and powerful NHE1 inhibitors as potentially selective anticancer drugs—an integral molecular/biochemical/metabolic/clinical approach after 100 years of cancer research. J Transl Med 11:282PubMedCentralPubMed
182.
Van Meir E (1996) Hypoxia-mediated selection of cells with diminished apoptotic potential to solid tumours. Neurosurgery 39:878–879PubMed
183.
Gatenby RA, Smallbone K, Maini PK, Rose F, Averill J, Nagle RB et al (2007) Cellular adaptations to hypoxia and acidosis during somatic evolution of breast cancer. Br J Cancer 97:646–653PubMedCentralPubMed
184.
Graeber TG, Osmanian C, Jacks T, Housman DE, Koch CJ, Lowe SW et al (1996) Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours. Nature 379:88–91PubMed
185.
Coquelle A, Toledo F, Stern S, Bieth A, Debatisse M (1998) A new role for hypoxia in tumor progression: induction of fragile site triggering genomic rearrangements and formation of complex DMs and HSRs. Mol Cell 2:259–265PubMed
186.
Vaupel P (2004) The role of hypoxia-induced factors in tumor progression. Oncologist 9(Suppl 5):10–17PubMed
187.
188.
Sakata K, Kwok TT, Murphy BJ, Laderoute KR, Gordon GR, Sutherland RM (1991) Hypoxia-induced drug resistance: comparison to P-glycoprotein-associated drug resistance. Br J Cancer 64:809–814PubMedCentralPubMed
189.
190.
Suzuki Y, Tanaka K, Neghishi D, Shimizu M, Murayama N, Hashimoto T et al (2008) Increased distribution of carboplatin, an anti-cancer agent, to rat brains with the aid of hyperbaric oxygenation. Xenobiotica 38:1471–1475PubMed
191.
Lara PC, Lloret M, Clavo B, Apolinario RM, Henríquez-Hernández LA, Bordón E et al (2009) Severe hypoxia induces chemo-resistance in clinical cervical tumors through MVP over-expression. Radiat Oncol 4:29PubMedCentralPubMed
192.
Kim JW, Ho WJ, Wu BM (2011) The role of the 3D environment in hypoxia-induced drug and apoptosis resistance. Anticancer Res 31:3237–3245PubMed
193.
Cosse J-P, Michiels C (2008) Tumour hypoxia affects the responsiveness of cancer cells to chemotherapy and promotes cancer progression. Anticancer Agents Med Chem 8:790–797PubMed
194.
Zhu H, Chen XP, Luo SF, Guan J, Zhang WG, Zhang BX (2005) Involvement of hypoxia-inducible factor-1-alpha in multidrug resistance induced by hypoxia in HepG2 cells. J Exp Clin Cancer Res 24:565–574PubMed
195.
Legendre C, Hori T, Loyer P, Aninat C, Ishida S, Glaise D et al (2009) Drug-metabolising enzymes are down-regulated by hypoxia in differentiated human hepatoma HepaRG cells: HIF-1alpha involvement in CYP3A4 repression. Eur J Cancer 45:2882–2892PubMed
196.
Sullivan R, Paré GC, Frederiksen LJ, Semenza GL, Graham CH (2008) Hypoxia-induced resistance to anticancer drugs is associated with decreased senescence and requires hypoxia-inducible factor-1 activity. Mol Cancer Ther 7:1961–1973PubMed
197.
Primeau AJ, Rendon A, Hedley D, Lilge L, Tannock IF (2005) The distribution of the anticancer drug Doxorubicin in relation to blood vessels in solid tumors. Clin Cancer Res 11(24 Pt 1):8782–8788PubMed
198.
Minchinton AI, Tannock IF (2006) Drug penetration in solid tumours. Nat Rev Cancer 6:583–592PubMed
199.
Leontieva OV, Natarajan V, Demidenko ZN, Burdelya LG, Gudkov AV, Blagosklonny MV (2012) Hypoxia suppresses conversion from proliferative arrest to cellular senescence. Proc Natl Acad Sci USA 109:13314–13318PubMedCentralPubMed
200.
Warburg O (1956) On the origin of cancer cells. Science 123:309–314PubMed
201.
Weinhouse S (1956) On respiratory impairment in cancer cells. Science 124:267–269PubMed
202.
Gatenby RA, Gillies RJ (2004) Why do cancers have high aerobic glycolysis? Nat Rev Cancer 4:891–899PubMed
203.
Williams B, Howard RL (1994) Glucose-induced changes in Na+/H+ antiport activity and gene expression in cultured vascular smooth muscle cells. Role of protein kinase C. J Clin Invest 93:2623–2631PubMedCentralPubMed
204.
Fu Y, Lee AS (2006) Glucose regulated proteins in cancer progression, drug resistance and immunotherapy. Cancer Biol Ther 5:741–744PubMed
205.
Lyon RC, Cohen JS, Faustino PJ, Megnin F, Myers CE (1988) Glucose metabolism in drug-sensitive and drug-resistant human breast cancer cells monitored by magnetic resonance spectroscopy. Cancer Res 48:870–877PubMed
206.
Cao X, Fang L, Gibbs S, Huang Y, Dai Z, Wen P et al (2007) Glucose uptake inhibitor sensitizes cancer cells to daunorubicin and overcomes drug resistance in hypoxia. Cancer Chemother Pharmacol 59:495–505PubMed
207.
Lee C, Raffaghello L, Brandhorst S, Safdie FM, Bianchi G, Martin-Montalvo A et al (2012) Fasting cycles retard growth of tumors and sensitize a range of cancer cell types to chemotherapy. Sci Transl Med 4:124ra27PubMedCentralPubMed
208.
Komurov K, Tseng J-T, Muller M, Seviour EG, Moss TJ, Yang L et al (2012) The glucose-deprivation network counteracts lapatinib-induced toxicity in resistant ErbB2-positive breast cancer cells. Mol Syst Biol 8:596PubMedCentralPubMed
209.
Sevick EM, Jain RK (1989) Geometric resistance to blood flow in solid tumors perfused ex vivo: effects of tumor size and perfusion pressure. Cancer Res 49:3506–3512PubMed
210.
Weiss L, Tveit E, Hultborn R (1985) Vascular resistance characteristics of 7,12-dimethylbenz(a)anthracene-induced rat mammary tumors and normal tissues as studied in vitro. Cancer Res 45:2478–2480PubMed
211.
Tveit E, Weiss L, Lundstam S, Hultborn R (1987) Perfusion characteristics and norepinephrine reactivity of human renal carcinoma. Cancer Res 47:4709–4713PubMed
212.
Trédan O, Galmarini CM, Patel K, Tannock IF (2007) Drug resistance and the solid tumor microenvironment. J Natl Cancer Inst 99:1441–1454PubMed
213.
Salnikov AV, Iversen VV, Koisti M, Sundberg C, Johansson L, Stuhr LB et al (2003) Lowering of tumor interstitial fluid pressure specifically augments efficacy of chemotherapy. FASEB J 17:1756–1758PubMed
214.
Késmárky G, Kenyeres P, Rábai M, Tóth K (2008) Plasma viscosity: a forgotten variable. Clin Hemorheol Microcirc 39:243–246PubMed
215.
Kwon O, Krishnamoorthy M, Cho YI, Sankovic JM, Banerjee RK (2008) Effect of blood viscosity on oxygen transport in residual stenosed artery following angioplasty. J Biomech Eng 130:011003PubMed
216.
Stetler-Stevenson WG, Aznavoorian S, Liotta LA (1993) Tumor cell interactions with the extracellular matrix during invasion and metastasis. Annu Rev Cell Biol 9:541–573PubMed
217.
Aoudjit F, Vuori K (2012) Integrin Signaling in Cancer Cell Survival and Chemoresistance. Chemother Res Pract 1–16
218.
Netti PA, Berk DA, Swartz MA, Grodzinsky AJ, Jain RK (2000) Role of extracellular matrix assembly in interstitial transport in solid tumors. Cancer Res 60:2497–2503PubMed
219.
Rintoul RC, Sethi T (2001) The role of extracellular matrix in small-cell lung cancer. Lancet Oncol 2:437–442PubMed
220.
Rintoul RC, Sethi T (2002) Extracellular matrix regulation of drug resistance in small-cell lung cancer. Clin Sci (Lond) 102:417–424
221.
Naci D, El Azreq M-A, Chetoui N, Lauden L, Sigaux F, Charron D et al (2012) α2β1 integrin promotes chemoresistance against doxorubicin in cancer cells through extracellular signal-regulated kinase (ERK). J Biol Chem 287:17065–17076PubMedCentralPubMed
222.
Haslam IS, Jones K, Coleman T, Simmons NL (2008) Induction of P-glycoprotein expression and function in human intestinal epithelial cells (T84). Biochem Pharmacol 76:850–861PubMed
223.
Schuetz EG, Beck WT, Schuetz JD (1996) Modulators and substrates of P-glycoprotein and cytochrome P4503A coordinately up-regulate these proteins in human colon carcinoma cells. Mol Pharmacol 49:311–318PubMed
224.
Yumoto R, Murakami T, Sanemasa M, Nasu R, Nagai J, Takano M (2001) Pharmacokinetic interaction of cytochrome P450 3A-related compounds with rhodamine 123, a P-glycoprotein substrate, in rats pretreated with dexamethasone. Drug Metab Dispos 29:145–151PubMed
225.
Aquilante CL, Letrent SP, Pollack GM, Brouwer KL (2000) Increased brain P-glycoprotein in morphine tolerant rats. Life Sci 66:47–51
226.
El Hafny B, Chappey O, Piciotti M, Debray M, Boval B, Roux F (1997) Modulation of P-glycoprotein activity by glial factors and retinoic acid in an immortalized rat brain microvessel endothelial cell line. Neurosci Lett 236:107–111PubMed
227.
Dürr D, Stieger B, Kullak-Ublick GA, Rentsch KM, Steinert HC, Meier PJ et al (2000) St John’s Wort induces intestinal P-glycoprotein/MDR1 and intestinal and hepatic CYP3A4. Clin Pharmacol Ther 68:598–604PubMed
228.
Jonsson O, Behnam-Motlagh P, Persson M, Henriksson R, Grankvist K (1999) Increase in doxorubicin cytotoxicity by carvedilol inhibition of P-glycoprotein activity. Biochem Pharmacol 58:1801–1806PubMed
229.
Anglicheau D, Pallet N, Rabant M, Marquet P, Cassinat B, Méria P et al (2006) Role of P-glycoprotein in cyclosporine cytotoxicity in the cyclosporine-sirolimus interaction. Kidney Int 70:1019–1025PubMed
230.
Takara K, Tanigawara Y, Komada F, Nishiguchi K, Sakaeda T, Okumura K (1999) Cellular pharmacokinetic aspects of reversal effect of itraconazole on P-glycoprotein-mediated resistance of anticancer drugs. Biol Pharm Bull 22:1355–1359PubMed
231.
Floren LC, Bekersky I, Benet LZ, Mekki Q, Dressler D, Lee JW et al (1997) Tacrolimus oral bioavailability doubles with coadministration of ketoconazole. Clin Pharmacol Ther 62:41–49PubMed
232.
Callaghan R, Riordan JR (1993) Synthetic and natural opiates interact with P-glycoprotein in multidrug-resistant cells. J Biol Chem 268:16059–16064PubMed
233.
Callaghan R, Higgins CF (1995) Interaction of tamoxifen with the multidrug resistance P-glycoprotein. Br J Cancer 71:294–299PubMedCentralPubMed
234.
Chen J, Balmaceda C, Bruce JN, Sisti MB, Huang M, Cheung YKK et al (2006) Tamoxifen paradoxically decreases paclitaxel deposition into cerebrospinal fluid of brain tumor patients. J Neurooncol 76:85–92PubMed
235.
Jovelet C, Bénard J, Forestier F, Farinotti R, Bidart JM, Gil S (2012) Inhibition of P-glycoprotein functionality by vandetanib may reverse cancer cell resistance to doxorubicin. Eur J Pharm Sci 46:484–491PubMed
236.
Xu H-B, Li L, Fu J, Mao X-P, Xu L-Z (2012) Reversion of multidrug resistance in a chemoresistant human breast cancer cell line by β-elemene. Pharmacology 89:303–312PubMed
Metadata
Title
Resistance to cancer chemotherapy: failure in drug response from ADME to P-gp
Authors
Khalid O Alfarouk
Christian-Martin Stock
Sophie Taylor
Megan Walsh
Abdel Khalig Muddathir
Daniel Verduzco
Adil H H Bashir
Osama Y Mohammed
Gamal O Elhassan
Salvador Harguindey
Stephan J Reshkin
Muntaser E Ibrahim
Cyril Rauch
Publication date
01-12-2015
Publisher
BioMed Central
Published in
Cancer Cell International / Issue 1/2015
Electronic ISSN: 1475-2867
DOI
https://doi.org/10.1186/s12935-015-0221-1

Other articles of this Issue 1/2015

Cancer Cell International 1/2015 Go to the issue

Primary research

microRNA-30b inhibits cell invasion and migration through targeting collagen triple helix repeat containing 1 in non-small cell lung cancer

Primary research

Effect of Matrine on HPAC cell migration by down-regulating the expression of MT1-MMP via Wnt signaling

Primary research

Ideal sphere-forming culture conditions to maintain pluripotency in a hepatocellular carcinoma cell lines

Primary research

Celastrol induces cell cycle arrest by MicroRNA-21-mTOR-mediated inhibition p27 protein degradation in gastric cancer

Review

The role of death-associated protein 3 in apoptosis, anoikis and human cancer

Primary research

GSK3β mediates pancreatic cancer cell invasion in vitro via the CXCR4/MMP-2 Pathway
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits